ImmuCell Turns a Corner: Supply Restored, Capacity Tripled, and Share Gains Accelerate

After years of backorder constraints, ImmuCell's focused strategy on First Defense is producing double-digit growth, record market share, and a 42% rally in 90 days.

ICCC · Earnings Call · 2026-08-14

The Strategic Pivot to First Defense

In late 2025, ImmuCell made a decisive shift: abandon the broad portfolio and bet on its flagship calf-scours preventative, First Defense. The move, driven by new CEO Oliver Te Boekhorst, was designed to solve a chronic supply problem that had constrained growth for years. The results are now speaking for themselves. As Oliver put it: “We are on track to produce nearly 1 million more manufacturing units this year than we did in 2025” (“we are on track to produce nearly 1 million more manufacturing units this year than we did in 2025” — P. F. Te Boekhorst, Chief Executive Officer · 2026-08-14). That restored supply has translated into revenue. Product sales for Q2 2026 rose 11.5% year-over-year to $7.2 million, with domestic sales up 27.7%. The first half of the year saw a 20.9% increase to $17.5 million. The company's capacity expansion is now the central theme, with two phases totaling $8 million that will more than triple current capacity. The investments leverage existing facilities and equipment from the discontinued Re-Tain product, turning a former liability into a growth asset. Management explicitly linked the expansion to reliable supply, a keyword that has climbed to the top of the company's trajectory (settlement from the former contract manufacturer provided $2 million in cash to partially fund this).

Market Share Gains from Commercial Execution

Beyond capacity, the company is seeing tangible traction in the field. The commercial team has been expanded, with new salespeople delivering ahead of plan. Most striking is the market share data: share of animals treated with a biological scours preventative rose from 15% in December 2025 to 19% by June 2026, while share of producer spending jumped from 29% to 38%. This is driven by a price point roughly twice that of competitors, yet the value proposition is compelling given improving calf economics—day-old calf values have risen from $400 to $1,700 since 2024. As Oliver explained, “We have to show up, ask the right questions and present the health and economic benefits of our solutions” (component 967120056883055284).

We increased our market share as well, defined as First Defense's share of animals treated with a biological scours preventative in the U.S. And we increased that market share from approximately 15% in December 2025 to approximately 19% at the end of June 2026.
P. F. Te Boekhorst, Chief Executive Officer · 2026-08-14

Gross Margin Dip is Near-Term, Not Structural

The second quarter gross margin fell to 33.9% from 43.7% a year ago—a decline that caught attention. Management dissected it into three parts: lower manufacturing output (7.5 points sequentially), $150,000 of scrap from a purchased material (2.1 points), and the recurring cost shift from Re-Tain into COGS (1.9 points). CFO Timothy Fiori was transparent: “This is the cost of the building. So it's utilities, depreciation associated with the building.” The margin drop is a function of timing and mix, not a step-change in competitiveness. Indeed, the company increased finished goods inventory during the quarter and expects yields to improve as process changes take hold. This is consistent with the longer-term trend. Gross margin has risen from 9% in early 2023 to 45% in the latest quarter, though the latest quarter excludes the Re-Tain cost shift. The capacity expansion is designed to improve product cost long-term, with new processes reducing total processing time from 2–3 months to under 1 month.

Financial Position and Backlog Lapping

Net income for Q2 was $1.8 million, boosted by the $2 million settlement; adjusted EBITDA of $2.7 million also benefited. Cash on hand stands at $8.9 million, and the company plans to self-fund the majority of the expansion. Working capital rose to $16.6 million. The company also confirmed that the distributor backlog from 2025 has been fully fulfilled, so future comparisons will be clean—a key overhang now removed. Prior calls had repeatedly flagged the backorder and supply constraints as the primary headwinds. In March 2026, Oliver said: “We are now stepping up our commercial activities... it's all about growth on the top line” (component 8246448365923517270). That shift is now reflected in the tape: the stock is up 42% in the last 90 days, recovering from a 15% drawdown off its 2021 peak. The company's Re-Tain investigation with Michigan State remains a wildcard, with results expected by September/October, but it is no longer the strategic focus. The market is watching the core story: supply reliability, market share growth, and a capacity pipeline that could triple output. Overall, this is a classic turnaround in motion: constrained supply resolved, commercial engine reengaged, and capital redeployed into scalable growth. The next few quarters will reveal whether the margin recovery and production ramp can keep pace with the rally.